Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 74.88% | 68.31% | 40.32% | 8.41% | -13.15% |
| Total Depreciation and Amortization | 16.29% | 12.95% | 3.79% | -3.41% | -3.61% |
| Total Amortization of Deferred Charges | -7.86% | -22.11% | -29.50% | -14.66% | 4.00% |
| Total Other Non-Cash Items | 41.09% | -37.87% | -56.18% | -89.84% | -51.09% |
| Change in Net Operating Assets | -288.89% | -485.39% | 468.29% | 221.18% | 435.46% |
| Cash from Operations | 62.05% | 65.31% | 47.97% | 9.70% | -10.43% |
| Capital Expenditure | -- | 14.90% | -134.53% | -364.41% | -119.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 887.76% | 1,076.74% | 249.59% | 179.32% | 71.00% |
| Cash from Investing | 834.95% | 1,042.32% | 248.43% | 178.62% | 69.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.98% | -- | -100.00% | -100.00% | -99.94% |
| Repurchase of Common Stock | 67.41% | 65.49% | 69.24% | 69.24% | -69.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -212.00% | -486.67% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 99.92% | -126.75% | -126.75% | -- |
| Cash from Financing | -120.35% | -119.16% | -119.48% | -100.38% | 26.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.54% | 228.28% | 122.12% | -147.67% | 285.05% |